Bedrosian Camille L sold $325K of AMLX

Amylyx Pharmaceuticals (AMLX) shares fell as investors took profits after a rally driven by positive Phase 3 data for avexitide. Concerns include valuation, dilution from a $500M stock offering, and insider sales. The company faces high funding needs for commercialization around 2027, shifting focus to financial costs and capital access.

Amylyx Pharmaceuticals (AMLX) shares rose 14% after-hours as it prepares to release Phase 3 trial results for avexitide, its lead drug candidate for post-bariatric hypoglycemia. The trial's success could support a 2027 regulatory filing. AMLX has no FDA-approved therapies currently, and its cash runway extends into 2028. Mizuho raised its price target to $30, citing potential launch pricing updates.

Amylyx Pharmaceuticals (AMLX) has surged 247% this year after positive trial results for its experimental treatment, avexitide, which met all endpoints. The company aims to submit avexitide for FDA approval by year-end, with analysts estimating $1.5B in peak U.S. sales. Amylyx recently raised $500M through a stock offering. The stock is trading at $34.74, with a market cap of $4.2B.

Amylyx Pharmaceuticals (AMLX) raised $500M, strengthening its balance sheet. Its experimental drug, avexitide, reduced serious hypoglycemic events by 55% in a phase 3 trial, with potential FDA submission by year-end. Analysts estimate peak U.S. sales at $1.5B. The stock has surged 247% year-to-date, but analysts suggest a pullback to $28-$30 per share for better entry.

Amylyx Pharmaceuticals (AMLX) completed a $575 million upsized public offering of common stock. Goodwin Procter LLP advised the company, while Wilmer Cutler Pickering Hale and Dorr LLP advised the underwriters.

Amylyx Pharmaceuticals (AMLX) shares surged 64% after positive trial data for avexitide, a treatment for post-bariatric hypoglycemia. The company launched a $350M share offering to fund pre-commercial work. Analysts raised price targets, with H.C. Wainwright setting a $55 target and Stifel at $45. AMLX has gained 200% YTD.